Are Investors Being Too Paranoid About Pfizer Stock?
All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...
Pfizer: 3 Key Risks That Warrant A Sell
Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...
Jefferies raises Pfizer stock price target to $34, maintains Buy
Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...
What Investors Are Missing about Pfizer and Merck
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Business Wire2d
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform
Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
Pfizer (NYSE:PFE) Shares Up 2.9% on Earnings Beat
Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 2.9% on Wednesday following a stronger than expected earnings ...
Pfizer's Groundbreaking Cancer Drug Hits a Major Milestone--What It Means for Investors
BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...
Pfizer Receives Expanded FDA Approval for Cancer Treatment
The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.